Bevacizumab/octreotideDiarrhoea, hypertension and epistaxis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1792卷 / 1期

关键词：

D O I：

10.1007/s40278-020-75162-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：54 / 54

相关论文

共 50 条

[1] Bevacizumab/fluorouracil/folinic acid/irinotecanNeutropenic sepsis, epistaxis and hypertension: 3 case reports
[J]. Reactions Weekly, 2015, 1552 (1) : 39 - 39
[2] Bevacizumab/carboplatin/vinorelbineDeep vein thrombosis and epistaxis: 2 case reports
[J]. Reactions Weekly, 2015, 1580 (1) : 65 - 65
[3] Bevacizumab/docetaxel/gemcitabineMyelosuppression and epistaxis: 3 case reports
[J]. Reactions Weekly, 2012, 1429 (1) : 11 - 11
[4] Bevacizumab/nivolumabThrombotic microangiopathy and hypertension: 2 case reports
[J]. Reactions Weekly, 2023, 1949 (1) : 104 - 104
[5] Bevacizumab/doxorubicinMyelosuppression and hypertension: 3 case reports
[J]. Reactions Weekly, 2022, 1888 (1) : 103 - 103
[6] Bevacizumab/ranibizumabOcular hypertension: 10 case reports
[J]. Reactions Weekly, 2021, 1877 (1) : 71 - 71
[7] BevacizumabWorsening of hypertension and epistaxis following off-label use: 2 case reports
[J]. Reactions Weekly, 2020, 1799 (1) : 97 - 97
[8] SildenafilFirst report of epistaxis: 2 case reports
[J]. Reactions Weekly, 2002, 932 (1) : 10 - 10
[9] AntineoplasticsThrombocytopenia, epistaxis and death: 2 case reports
[J]. Reactions Weekly, 2019, 1742 (1) : 36 - 36
[10] AspirinBruising, bleeding and epistaxis: 2 case reports
[J]. Reactions Weekly, 2021, 1872 (1) : 69 - 69

← 1 2 3 4 5 →